标题
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
作者
关键词
-
出版物
Nature Communications
Volume 8, Issue -, Pages 15617
出版商
Springer Nature
发表日期
2017-06-08
DOI
10.1038/ncomms15617
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
- (2016) F. J. Sanchez-Martin et al. CLINICAL CANCER RESEARCH
- MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
- (2016) Sabrina Arena et al. Science Translational Medicine
- Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
- (2015) M. P. Morelli et al. ANNALS OF ONCOLOGY
- Mapping the Pathways of Resistance to Targeted Therapies
- (2015) K. C. Wood CANCER RESEARCH
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
- (2015) S. Arena et al. CLINICAL CANCER RESEARCH
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- Targeting the translation machinery in cancer
- (2015) Mamatha Bhat et al. NATURE REVIEWS DRUG DISCOVERY
- Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
- (2015) Sandra Misale et al. Nature Communications
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
- (2015) Enzo Medico et al. Nature Communications
- Rare codons capacitate Kras-driven de novo tumorigenesis
- (2014) Nicole L.K. Pershing et al. JOURNAL OF CLINICAL INVESTIGATION
- eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
- (2014) Lise Boussemart et al. NATURE
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis
- (2014) P. S. Winter et al. Science Signaling
- Systematic identification of signaling pathways with potential to confer anticancer drug resistance
- (2014) C. A. Martz et al. Science Signaling
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
- (2014) S. Misale et al. Cancer Discovery
- KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
- (2012) C. Miranda et al. CLINICAL CANCER RESEARCH
- Rare Codons Regulate KRas Oncogenesis
- (2012) Benjamin L. Lampson et al. CURRENT BIOLOGY
- A public genome-scale lentiviral expression library of human ORFs
- (2011) Xiaoping Yang et al. NATURE METHODS
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
- (2011) A. S. Little et al. Science Signaling
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Allosteric modulation of Ras positions Q61 for a direct role in catalysis
- (2010) G. Buhrman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- SUnSET, a nonradioactive method to monitor protein synthesis
- (2009) Enrico K Schmidt et al. NATURE METHODS
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
- (2008) A Agarwal et al. LEUKEMIA
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search